Literature DB >> 24652221

Influence of dialysis techniques and alternate vitamin supplementation on homocysteine levels in patients with known MTHFR genotypes.

Mariarita Dessì1, Gianna Di Giovamberardino, Massimo Pieri, Annalisa Noce, Rossella Zenobi, Nicola Di Daniele, Anna Pastore.   

Abstract

BACKGROUND: Treatment with folic acid and vitamin B12 appears capable of reducing total plasma homocysteine levels (tHcy), but it is unknown whether vitamin B12 alone reduces tHcy values. In this study we investigate the effects of alternate vitamins supplementation on homocysteine levels in patients treated by diffusive and convective dialysis techniques.
METHODS: 74 patients were randomized blindly into two groups of 37 subjects each. The first group was treated initially with vitamin B12 for 2 months and with folic acid for the following 2 months. The second group was treated initially with folic acid. A wash out period of 2 months followed the treatment in both groups.
RESULTS: Total homocysteine levels decreased in both groups following the alternate vitamins therapy and dialysis, without significant difference between diffusive and convective techniques. Surprisingly, after the wash-out period, tHcy increased remarkably, regardless of the dialysis procedure used. At the end of the study, folate levels showed a higher reduction with haemodialysis compared to haemodiafiltration. In contrast, vitamin B12 levels showed a significant increase using diffusive haemodialysis, confirming a decisive role of membrane performance.
CONCLUSIONS: In conclusion we show for the first time that, even if total homocysteine levels decreased in both dialysis procedures, the convective techniques demonstrate a superior capacity on the reduction of tHcy levels compared to the diffusive method. Moreover, the lower depletion of vitamin B12 by diffusive techniques could determine a higher reduction of folate levels, demonstrating the decisive role of the membrane performance in the treatment of this patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24652221     DOI: 10.1007/s10157-014-0961-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  22 in total

1.  B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.

Authors:  Judith Heinz; Siegfried Kropf; Ute Domröse; Sabine Westphal; Katrin Borucki; Claus Luley; Klaus H Neumann; Jutta Dierkes
Journal:  Circulation       Date:  2010-03-15       Impact factor: 29.690

2.  Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes.

Authors:  Anna Pastore; Sandro De Angelis; Stefania Casciani; Rosalba Ruggia; Gianna Di Giovamberardino; Annalisa Noce; Giorgio Splendiani; Claudio Cortese; Giorgio Federici; Mariarita Dessi'
Journal:  Clin Chem       Date:  2006-01       Impact factor: 8.327

3.  Parenteral vitamin B12 reduces hyperhomocysteinemia in end-stage renal disease.

Authors:  L N Kaplan; O A Mamer; L J Hoffer
Journal:  Clin Invest Med       Date:  2001-02       Impact factor: 0.825

4.  Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B in kidney transplant recipients.

Authors:  Wolfgang C Winkelmayer; Andrea Huber; Oswald F Wagner; Walter H Hörl; Gere Sunder-Plassmann; Manuela Födinger
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

5.  Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study.

Authors:  A G Bostom; D Shemin; P Verhoef; M R Nadeau; P F Jacques; J Selhub; L Dworkin; I H Rosenberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

6.  Impact of high-flux/high-efficiency dialysis on folate and homocysteine metabolism.

Authors:  C Lasseur; F Parrot; Y Delmas; C Level; C Ged; I Redonnet-Vernhet; D Montaudon; C Combe; P Chauveau
Journal:  J Nephrol       Date:  2001 Jan-Feb       Impact factor: 3.902

7.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.

Authors:  P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

8.  Randomized, placebo-controlled trial of intramuscular vitamin B12 for the treatment of hyperhomocysteinaemia in dialysis patients.

Authors:  K R Polkinghorne; S Zoungas; P Branley; E Villanueva; J J McNeil; R C Atkins; B P McGrath; P G Kerr
Journal:  Intern Med J       Date:  2003-11       Impact factor: 2.048

9.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase.

Authors:  S S Kang; J Zhou; P W Wong; J Kowalisyn; G Strokosch
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

10.  Selective adsorption of homocysteine using an HFR-ON LINE technique.

Authors:  Giorgio Splendiani; Sandro De Angelis; Tiziana Tullio; Michele Ferranini; Maria Rita Dessì; Anna Pastore; Stefania Casciani; Laura Liberatoscioli; Giorgio Federici; Claudio Cortese
Journal:  Artif Organs       Date:  2004-06       Impact factor: 3.094

View more
  1 in total

Review 1.  The Impact of Chronic Kidney Disease on Nutritional Status and Its Possible Relation with Oral Diseases.

Authors:  Micaela Costacurta; Michele Basilicata; Giulia Marrone; Manuela Di Lauro; Vincenzo Campolattano; Patrizio Bollero; Raffaella Docimo; Nicola Di Daniele; Annalisa Noce
Journal:  Nutrients       Date:  2022-05-10       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.